Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 35, 2020 - Issue 1
Submit an article Journal homepage
1,336
Views
3
CrossRef citations to date
0
Altmetric
Short Communication

Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors

Daseul ImCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaView further author information
,
Hyungwoo MoonCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaView further author information
,
Jinwoong KimCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaView further author information
,
Youri OhCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaView further author information
,
Miyoung JangCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaView further author information
&
Jung-Mi HahCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, KoreaCorrespondence[email protected]
View further author information
Pages 1110-1115 | Received 26 Dec 2019, Accepted 10 Apr 2020, Published online: 27 Apr 2020

References

  • Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176–85.
  • Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588–99.
  • Zhang S, Fukuda S, Lee Y, et al. essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000;192:719–28.
  • Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: Biology and therapeutic implications. J Hematol Oncol 2011;1:1–10.
  • Gary Gilliland D, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–42.
  • Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther 2017;16:991–1001.
  • Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs 2017;35:556–65.
  • Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol 2017;18:1061–75.
  • Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci 2015;36:422–39.
  • Versele M, Haefner B, Wroblowski B, et al. Covalent Flt3-Cys828 inhibition represents a novel therapeutic approach for the treatment of Flt3- ITD and Flt3-D835 mutant acute myeloid leukemia. Cancer Res 2016;76:4800.
  • Im D, Jung K, Yang S, et al. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors. Eur J Med Chem 2015;102:600–10.
  • Im D, Moon H, Kim J, et al. Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl- N-(2-aryl-1H-benzo[d]imidazo-5-yl)isoxazole-4-carboxamide analogues as selective FLT3 inhibitors. J Enzyme Inhib Med Chem 2019;34:1716–21.
  • Kamal A, Reddy K, Devaiah V, et al. Recent advances in the solid-phase combinatorial synthetic strategies for the quinoxaline, quinazoline and benzimidazole based privileged structures. Mini-Rev Med Chem 2006;6:71–89.
  • Chen Y, Pan Y, Guo Y, et al. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig 2017;4:48–13.
  • Smith CC, Lin K, Stecula A, et al. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 2015;29:2390–2.
  • Levis M. FLT3 mutations in acute myeloid leukemia?: What is the best approach in 2013? Hematology Am Soc Hematol Educ Program 2013;2013:220–6.
  • Sun D, Yang Y, Lyu J, et al. Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants. J Med Chem 2016;59:6187–200.
  • Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 2019;144:19–50.
  • Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur J Haematol 2017;98:330–6.
  • Chen Y, Pan Y, Guo Y, et al. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Invest 2017;4:48–52.
  • Warkentin AA, Lopez MS, Lasater EA, et al. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife 2014;3:e03445.
  • Liang X, Wang B, Chen C, et al. Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent Fms-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia. J Med Chem 2019;62:875–892.
  • Smith CC, Lin KC, Zhang Y, et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397. Cancer Discov 2015;5:668–79.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.